Oral Health Care Drug Products for Over-the-Counter Human Use; Antigingivitis/Antiplaque Drug Products; Establishment of a Monograph

ローカル自動翻訳 · 情報源の原言語

概要

The Food and Drug Administration (FDA) is issuing an advance notice of proposed rulemaking that would establish conditions under which over-the-counter (OTC) drug products for the reduction or prevention of dental plaque and gingivitis are generally recognized as safe and effective and not misbranded. This notice is based on the recommendations of the Dental Plaque Subcommittee of the Nonprescription Drugs Advisory Committee (NDAC) and is part of FDA's ongoing review of OTC drug products.

情報源の原言語: Federal Register — Food and Drug Administration原文の発表を開く →

Oral Health Care Drug Products for Over-the-Counter Human Use; Antigingivitis/Antiplaque Drug Products; Establishment of a Monograph

Office of Management and Budget (OMB) に提出された情報収集活動; Food and Drug Administration (FDA) の提出書類の提出; Customer/Partner Customer Service Satisfaction Surveys に関するコメントの要求

CDCのデータ収集計画についての意見募集

Agency Information Collection Activities: Proposed Collection; Comment Request

Office of the National Coordinator for Health Information Technology; Health Information Technology Advisory Committee; エンタイントにそすにしたプログルにしたプログにプログを定义にしたプログに。